Comparative Pharmacology
Head-to-head clinical analysis: CHOLOVUE versus CONRAY 43.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOVUE versus CONRAY 43.
CHOLOVUE vs CONRAY 43
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Complexes with anions in the gastrointestinal tract to increase fecal elimination of iodipamide, reducing systemic absorption and enhancing gallbladder visualization.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
100 mg/kg intravenously over 30 minutes every 3-4 weeks.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in patients with normal renal function; prolonged to 15–20 hours in moderate renal impairment (CrCl 30–50 mL/min) and >24 hours in severe renal failure.
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal; approximately 70% excreted unchanged in urine within 24 hours, with the remainder eliminated as glucuronide conjugates via biliary/fecal route (20%) and minor metabolic pathways (10%).
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent